Axonics (AXNX)
(Delayed Data from NSDQ)
$66.93 USD
+0.24 (0.36%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $66.85 -0.08 (-0.12%) 4:32 PM ET
2-Buy of 5 2
D Value A Growth C Momentum B VGM
Price, Consensus and EPS Surprise
AXNX 66.93 +0.24(0.36%)
Will AXNX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AXNX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AXNX
All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy
Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System
AXNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Axonics Modulation Technologies (AXNX) Q4 Earnings and Revenues Surpass Estimates
American Well Corporation (AMWL) Reports Q4 Loss, Tops Revenue Estimates
Zacks.com featured highlights include Axonics, Enerpac Tool Group, Cardinal Health and Acuity Brands
Other News for AXNX
Boston Scientific Announces Results for First Quarter 2024
Wells Fargo Sticks to Its Hold Rating for Axonics Modulation Technologies (AXNX)
FDA Classifies Boston Scientific's Recall For Device To Stop Blood Flow As 'Most Serious'
RBC Capital Remains a Hold on Axonics Modulation Technologies (AXNX)
RBC Capital Sticks to Its Hold Rating for Axonics Modulation Technologies (AXNX)